Antifungal activity study on HDAC inhibitor Rocilinostat
10.12206/j.issn.1006-0111.202103008
- VernacularTitle:组蛋白去乙酰化酶抑制剂Rocilinostat的抗真菌活性研究
- Author:
Tianbao ZHU
1
;
Jie TU
2
;
Chunquan SHENG
2
;
Defeng XU
3
;
Na LIU
2
Author Information
1. School of Pharmacy, Changzhou University, Changzhou 213164，China;School of Pharmacy, Naval Medical University, Shanghai 200433，China.
2. School of Pharmacy, Naval Medical University, Shanghai 200433，China.
3. School of Pharmacy, Changzhou University, Changzhou 213164，China.
- Keywords:
HDAC inhibitors;
in vitro synergistic antifungal activity;
resistant;
Candida albicans
- From:
Journal of Pharmaceutical Practice
2022;40(1):44-47
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the in vitro synergistic antifungal activity of HDAC inhibitors in combination with azole drugs against azoles-resistant Candida strains. Methods The checkerboard microdilution method was used to evaluate the antifungal activity of the HDAC inhibitors in combination with azole drugs against clinically drug-resistant strains. The fungistatic activity and toxicity of Rocilinostat was determined through time-growth curve assay and cytotoxicity assay. Results The compound Rocilinostat combined with azole drugs showed excellent synergistic antifungal activity against a variety of azoles-resistant Candida albicans and Candida glabrata. The combination of high concentration Rocilinostat with FLC exhibited fungistatic effects. Very low toxicity was detected with Rocilinostat towards normal cells. Rocilinostat showed better HDAC inhibitory activity than SAHA. Conclusion As a fungi HDAC inhibitor, Rocilinostat has excellent in vitro synergistic antifungal activity and no severe toxicity to normal human cells.
